Beovu® is the commercial brand name of Brolucizumab Injection, a high-concentration single-chain variable fragment anti-VEGF monoclonal antibody developed by Novartis. It binds vascular endothelial growth factor A (VEGF-A) potently to block pathological retinal neovascularization and vascular leakage via intravitreal administration, stabilizing retinal structure and visual function.
Main Indications
Treatment of neovascular age-related macular degeneration (nAMD) in adult patients.
Clinical Research
Global multicenter phase III pivotal trials demonstrated that brolucizumab delivers long-term sustained anti-VEGF efficacy, supporting extended dosing intervals while maintaining significant reduction in macular fluid and stable visual acuity benefits;
Registration clinical trials enrolling Chinese patients confirmed durable anatomical improvement and comparable efficacy and safety profiles versus global trial populations;
Real-world long-term observational studies validated its advantage of fewer intravitreal injections to lower overall treatment burden for nAMD patients.
Common Side Effects
Severe adverse reactions: Intraocular inflammation, retinal vasculitis, retinal artery occlusion, endophthalmitis, retinal detachment (rare but sight-threatening);
Common mild adverse reactions: Conjunctival hemorrhage, ocular pain, transient blurred vision, vitreous floaters, temporary intraocular pressure elevation, eye irritation after injection.
Approval Status in China
Beovu® (Brolucizumab Injection, 19.8mg/0.165mL per vial) was approved for marketing in China in 2022. It is a prescription ophthalmic biological agent for intravitreal injection.
Buy Beovu (Brolucizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
